Graft-versus-host immune tolerance following TLI/ATS/CTX conditioning for MHC-mismatched allogeneic BMT for β-thal. (A) Kaplan-Meier analysis of cumulative survival (%) for all mice in each conditioning group (left) and mean ± SEM body mass (grams) of those mice engrafting by day 28 (right) among β-thal^+/− HW-80 recipients of WT BALB/c BMT following TBI-containing conditioning. Data are cumulative (n = 28 experiments). Number represents cumulative dose (cGy) TBI (eg, TBI 300, 300 cGy TBI). +, Time point at which 3 or fewer survivors remain in the specified treatment group. (B) Cumulative survival (%) for all mice in each conditioning group (left) and mean ± SEM body mass (grams) of those mice engrafting by day 28 (right) among β-thal^+/− HW-80 recipients of TLI-based conditioning or control ATS/CTX conditioning followed by WT BALB/c BMT. Data are cumulative (n = 28 experiments). (C) Mean ± SEM cumulative GVHD scores (left) and colon GVHD scores (right) of those mice engrafting by day 28 among BMT recipients shown in panels A and B. Data are cumulative (n = 28 experiments). (D) Representative photomicrographs of hematoxylin and eosin–stained sections of colon (40×) (top) and liver showing portal triad (40×) (bottom) from selected groups shown in panel C.